305 related articles for article (PubMed ID: 24730335)
21. Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.
Bolli GB; Lucidi P; Porcellati F; Fanelli CG
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S220-4. PubMed ID: 21525459
[No Abstract] [Full Text] [Related]
22. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
[No Abstract] [Full Text] [Related]
23. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Arnolds S; Rave K
Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
[No Abstract] [Full Text] [Related]
24. Insulin management of type 2 diabetes mellitus.
Petznick A
Am Fam Physician; 2011 Jul; 84(2):183-90. PubMed ID: 21766768
[TBL] [Abstract][Full Text] [Related]
25. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
[TBL] [Abstract][Full Text] [Related]
26. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
[No Abstract] [Full Text] [Related]
27. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
28. Summaries for patients. Comparison of two types of insulin added to diabetes pills in poorly controlled type 2 diabetes.
Ann Intern Med; 2008 Oct; 149(8):I-46. PubMed ID: 18936498
[No Abstract] [Full Text] [Related]
29. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
Roach P; Malone JK
Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
[TBL] [Abstract][Full Text] [Related]
30. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
Varewijck AJ; Janssen JA; Vähätalo M; Hofland LJ; Lamberts SW; Yki-Järvinen H
Diabetologia; 2012 Apr; 55(4):1186-94. PubMed ID: 22237688
[TBL] [Abstract][Full Text] [Related]
31. [Long acting insulin analogues: results of clinical studies with insulin glargine].
Fritsche A
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S101-5; discussion S124-6. PubMed ID: 18686217
[TBL] [Abstract][Full Text] [Related]
32. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
34. Learning from ORIGIN.
Bloomgarden ZT
J Diabetes; 2012 Sep; 4(3):191-2. PubMed ID: 22716648
[No Abstract] [Full Text] [Related]
35. [Insulin therapy in type 2 diabetes].
Hummel M
MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
[No Abstract] [Full Text] [Related]
36. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
Davies M; Lavalle-González F; Storms F; Gomis R;
Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
[TBL] [Abstract][Full Text] [Related]
37. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
38. Response to type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach.
Ramón Calle J
South Med J; 2005 Sep; 98(9):958-9. PubMed ID: 16218000
[No Abstract] [Full Text] [Related]
39. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
40. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
